Rumanija - Rumen - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

gedeon richter plc. - ungaria - fentanylum - sol. inj. - 50micrograme/ml - anestezice generale anestezice opioide

Unjoni Ewropea - Rumen - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agenți antineoplazici - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq cum este indicat în monoterapie pentru tratamentul pacienților adulți cu nsclc local avansat sau metastatic după chimioterapie anterioară. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq cum este indicat în monoterapie pentru tratamentul pacienților adulți cu nsclc local avansat sau metastatic după chimioterapie anterioară. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Rumanija - Rumen - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

heaton k.s. - republica ceha - alfacalcidolum - caps. moi - 0,50micrograme - vitamina a si d (incl. combinatii) vitamina d si analogi

Rumanija - Rumen - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

laboratori fundacio dau - spania - levothyroxinum - compr. - 50micrograme - preparate de tiroida hormoni tiroidieni

Rumanija - Rumen - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

cis bio international - franta - tc 99m - pertechnetate - generator de radionuclizi - 2-50gbq - tiroida preparate pentru radiodiagnostic la nivelul tiroidei, varia

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

roche registration ltd - trastuzumabum - pulbere pentru solutie perfuzabila - 150 mg

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

roche registration ltd - rituximabum - concentrat pentru solutie perfuzabila - 500 mg/50 ml

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

roche registration ltd - rituximabum - concentrat pentru solutie perfuzabila - 100 mg/10 ml

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

roche registration ltd - metoxi polietilen glicol-epoetină beta - solutie injectabila in seringa preumpluta - 50 mcg/0,3 ml

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

roche registration ltd - peginterferonum alfa-2a - solutie injectabila in seringa preumpluta - 135 mcg/0,5 ml